ArticleCancer research2014
Oncogene pathway activation in mammary tumors dictates FDG-PET uptake.
Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 67 citations in OpenAlex.
- [Molecular cancer · 2026Article
- ATAD2 as a Cancer Target: Insights into Its Structure, Functions, Mechanisms, and Drug Development.Cancers · 2025Review
- Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.Oncogene · 2025Article
- Clinical value ofCellular oncology (Dordrecht, Netherlands) · 2024Article
- Article
- Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence.Science advances · 2024Article
- B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.Cancer cell · 2024Article
- Prognostic value of glucose transporter proteins-1 (GLUT1) in breast carcinoma.The Libyan journal of medicine · 2023Article
- Differences in Tumour Aggressiveness Based on Molecular Subtype and Race Measured by [Diagnostics (Basel, Switzerland) · 2023Article
- PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.Breast cancer research : BCR · 2023Article
- In vivo metabolic imaging identifies lipid vulnerability in a preclinical model of Her2+/Neu breast cancer residual disease and recurrence.NPJ breast cancer · 2022Article
- Article
- Article
- PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (xMolecular imaging and biology · 2020Article
- Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy.Science advances · 2020Article
- Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Adenine Nucleotide Translocase 2 as an Enzyme Related to [Molecular imaging and biology · 2019Article
- Optical Imaging of Glucose Uptake and Mitochondrial Membrane Potential to Characterize Her2 Breast Tumor Metabolic Phenotypes.Molecular cancer research : MCR · 2019Article
- ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway.BMB reports · 2019Article
- Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer.Oncotarget · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Increased glucose utilization is a hallmark of human cancer that is used to image tumors clinically. In this widely used application, glucose uptake by tumors is monitored by positron emission tomography of the labeled glucose analogue 2[(18)F]fluoro-2-deoxy-D-glucose (FDG). Despite its widespread clinical use, the cellular and molecular mechanisms that determine FDG uptake--and that underlie the heterogeneity observed across cancers-remain poorly understood. In this study, we compared FDG uptake in mammary tumors driven by the Akt1, c-MYC, HER2/neu, Wnt1, or H-Ras oncogenes in genetically engineered mice, correlating it to tumor growth, cell proliferation, and expression levels of gene involved in key steps of glycolytic metabolism. We found that FDG uptake by tumors was dictated principally by the driver oncogene and was not independently associated with tumor growth or cellular proliferation. Oncogene downregulation resulted in a rapid decrease in FDG uptake, preceding effects on tumor regression, irrespective of the baseline level of uptake. FDG uptake correlated positively with expression of hexokinase-2 (HK2) and hypoxia-inducible factor-1α (HIF1α) and associated negatively with PFK-2b expression and p-AMPK. The correlation between HK2 and FDG uptake was independent of all variables tested, including the initiating oncogene, suggesting that HK2 is an independent predictor of FDG uptake. In contrast, expression of Glut1 was correlated with FDG uptake only in tumors driven by Akt or HER2/neu. Together, these results demonstrate that the oncogenic pathway activated within a tumor is a primary determinant of its FDG uptake, mediated by key glycolytic enzymes, and provide a framework to interpret effects on this key parameter in clinical imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.